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Abstract
Transferring large or multiple genes into primary human stem/
progenitor cells is challenged by restrictions in vector capacity,
and this hurdle limits the success of gene therapy. A paradigm is
Duchenne muscular dystrophy (DMD), an incurable disorder caused
by mutations in the largest human gene: dystrophin. The combina-
tion of large-capacity vectors, such as human artificial chromo-
somes (HACs), with stem/progenitor cells may overcome this
limitation. We previously reported amelioration of the dystrophic
phenotype in mice transplanted with murine muscle progenitors
containing a HAC with the entire dystrophin locus (DYS-HAC).
However, translation of this strategy to human muscle progenitors
requires extension of their proliferative potential to withstand
clonal cell expansion after HAC transfer. Here, we show that rever-
sible cell immortalisation mediated by lentivirally delivered excis-
able hTERT and Bmi1 transgenes extended cell proliferation,
enabling transfer of a novel DYS-HAC into DMD satellite cell-
derived myoblasts and perivascular cell-derived mesoangioblasts.
Genetically corrected cells maintained a stable karyotype, did not
undergo tumorigenic transformation and retained their migration
ability. Cells remained myogenic in vitro (spontaneously or upon
MyoD induction) and engrafted murine skeletal muscle upon trans-
plantation. Finally, we combined the aforementioned functions
into a next-generation HAC capable of delivering reversible immor-
talisation, complete genetic correction, additional dystrophin
expression, inducible differentiation and controllable cell death.
This work establishes a novel platform for complex gene transfer
into clinically relevant human muscle progenitors for DMD gene
therapy.
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Introduction
Duchenne muscular dystrophy (DMD) is the most common muscle
disorder of childhood and one of the most severe forms of muscular
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dystrophy that leads to progressive muscle wasting and premature
death (Mercuri & Muntoni, 2013a). DMD is caused by mutations in
the X-linked dystrophin gene, which encodes for a protein responsi-
ble for sarcolemma integrity (Hoffman et al, 1987). Despite exten-
sive pre-clinical work and many novel clinical trials (Benedetti et al,
2013; Mercuri & Muntoni, 2013b; Bengtsson et al, 2016), currently
there are no definitive treatments. One of the main obstacles to the
development of an effective gene therapy for DMD is the large size
of the dystrophin gene (2.4 Mb), preventing cloning of its full cDNA
(14 kb) into conventional gene therapy vectors. This limitation is
then amplified by the abundance of degenerating skeletal muscle
needing repair or regeneration.
In recent years, a new generation of large cloning capacity
gene delivery vectors named human artificial chromosomes
(HACs) has been developed (Kazuki & Oshimura, 2011;
Kouprina et al, 2014; Oshimura et al, 2015; Tedesco, 2015).
HACs present several advantages for DMD gene therapy, includ-
ing (i) the ability to carry large DNA sequences such as entire
genetic loci, thus resulting in a more physiological expression
of genes with complex transcriptional regulation (including
dystrophin), (ii) stable episomal maintenance of a single copy
gene, avoiding the risk of insertional oncogenesis. In this
context, a HAC containing the entire dystrophin locus (DYS-
HAC) was engineered for ex vivo stem cell gene therapy of
DMD (Hoshiya et al, 2009).
In the last two decades, several populations of stem/progeni-
tor cells with myogenic potential have been isolated (Tedesco
et al, 2010, 2017), but so far only satellite cell-derived myoblasts
(Perie et al, 2014; Skuk & Tremblay, 2014), muscle pericyte-
derived mesoangioblasts (Cossu et al, 2015) and (to a minor
extent) muscle-derived AC133+ cells (Torrente et al, 2007) have
undergone clinical experimentation. We have shown that trans-
plantation of murine dystrophic mesoangioblasts corrected with a
DYS-HAC ameliorated the phenotype of dystrophic mdx mice
(Tedesco et al, 2011). These results provided the first evidence
of safe and efficacious pre-clinical gene replacement therapy with
a HAC into an animal model of a genetic disease, paving the
way for translating HAC gene transfer to human cells. However,
proliferation of human and murine cells is regulated by different
pathways, often resulting in a limited lifespan of human somatic
cells. Therefore, primary human muscle cells are likely to
require an extension of their proliferative potential to withstand
selection of corrected cells and subsequent expansion to
clinically relevant numbers after clonal HAC transfer [in the
range of 109 cells (Cossu et al, 2015)].
Here, we developed a novel genetic correction strategy based
upon the use of reversibly immortalising lentiviral vectors to
extend the proliferative potential of human myoblasts and
mesoangioblasts. We show that DMD muscle progenitor cells
immortalised by means of lentiviral vectors expressing the excis-
able catalytic subunit of human telomerase (hTERT) and the cell
cycle regulator Bmi1 (Cudre-Mauroux et al, 2003) enable transfer
of a novel DYS-HAC. Moreover, the presence of the herpes
simplex virus thymidine kinase (HSV-TK) cDNA between loxP
sites allows selective drug-induced elimination of target cells that
escaped transgene excision by Cre recombination (Salmon et al,
2000). DMD, reversibly immortalised, DYS-HAC-corrected progeni-
tors were transplanted in mouse models of acute and chronic
muscle injury, where they engrafted regenerating skeletal muscle.
Lastly, we combined all relevant gene functions into a single
next-generation synthetic HAC capable of delivering reversible
immortalisation, complete genetic correction, additional dystro-
phin expression, inducible differentiation and controllable cell
death, generating the largest and possibly most complex gene
therapy vector developed to date.
Results
Generation of a novel human artificial chromosome containing
the entire human dystrophin locus
To facilitate pre-clinical development of the DYS-HAC platform for
human myogenic cells, we engineered a novel DYS-HAC devoid of
potentially immunogenic gene products such as the enhanced green
fluorescent protein (EGFP), blasticidin (Bsd), HSV1-TK (Tk) and
hypoxanthine-guanine phosphoribosyltransferase (HPRT). For simplic-
ity, the DYS-HAC previously engineered (Hoshiya et al, 2009) and
used in our former murine study (Tedesco et al, 2011) is here renamed
DYS-HAC1, to distinguish it from the newly generated DYS-HAC2.
DYS-HAC2 was engineered by homologous recombination-mediated
DYS-HAC1 modifications (Fig 1A). In order to remove EGFP, Bsd,
HPRT and HSV1-TK genes from DYS-HAC1 and to add the floxable
(FRT) neomycin (Neo) gene for selection and lox71 site and 50 HPRT
for further gene insertion, the targeting vector pN (Fig 1A), containing
both the Neo gene and the regions for homologous recombination (A:
▸Figure 1. Generation of a novel HAC containing the entire human dystrophin locus by homologous recombination.A The scheme shows a linearised map of the vectors and the strategy used to generate DYS-HAC2 by homologous recombination of DYS-HAC1 (Hoshiya et al, 2009). pN
targeting vector, which contains regions for homologous recombination (A: 3.8 kb and B: 2.6 kb, in green) and a floxable (FRT) neomycin (Neo), was used to remove
extra genes (EGFP, Bsd, HPRT and Tk) on DYS-HAC1 and to insert a floxable Neo gene. Primers designed to amplify DYS-HAC1 or DYS-HAC2 specific regions are
highlighted in red.
B Phase contrast (left) and fluorescence (EGFP, right) images of DT40 cells containing DYS-HAC1 and DYS-HAC2. Scale bar: 50 lm.
C PCR analyses to discriminate between DYS-HAC1 and DYS-HAC2. DT40 cells: negative control.
D PCR panel to detect dystrophin exons in DT40(DYS-HAC1) and DT40(DYS-HAC2) cells. DT40 cells: negative control; human mesoangioblasts: positive control.
E In situ fluorescence hybridisation (FISH) analysis of DT40(DYS-HAC2) cells. White arrowheads: DYS-HAC2. Red: rhodamine-human COT-1 DNA; green: dystrophin FITC-
DMD-BAC RP11-954B16; yellow: merge. Scale bar: 5 lm. DT40(DYS-HAC2) hybrid was used to transfer the DYS-HAC2 in CHO cells (complete list in Appendix Table S1).
F FISH analyses of CHO(DYS-HAC2)-7 (left) and A9(DYS-HAC2)-9 (right) clones. White arrowheads: DYS-HAC2. CHO(DYS-HAC2) hybrid was used to transfer DYS-HAC2
in A9 cells (complete list in Appendix Table S2). Red/purple: rhodamine-human COT-1 DNA; green: dystrophin FITC-DMD-BAC RP11-954B16; yellow: merge.
Scale bar: 5 lm.
Source data are available online for this figure.
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3.8 kb and B: 2.6 kb), was introduced by electroporation into chicken
lymphoid DT40 cells already containing DYS-HAC1 [DT40(DYS-
HAC1)]. DT40 hybrids were then subjected to G418 (neomycin) selec-
tion, and 19 G418-resistant DT40 hybrids were randomly selected for
further analysis. One clone was found to be EGFP negative (Fig 1B),
indicating successful homologous recombination. PCRs using primers
able to discriminate DYS-HAC2 from DYS-HAC1 confirmed correct
targeting (Fig 1C), whereas another set of primers designed on the
dystrophin gene confirmed sequence integrity (Fig 1D). Finally, FISH
analysis established that DYS-HAC2 segregated independently without
host genome insertions or translocations (Fig 1E).
The novel DYS-HAC2 was then transferred via microcell-
mediated chromosome transfer (MMCT) from DT40(DYS-HAC2)
cells into Chinese hamster ovary (CHO) cells, to scale-up production
of microcells for HAC transfer. Twenty CHO(DYS-HAC2) clones were
randomly picked after G418 selection and both PCR and FISH con-
firmed the presence of a single episomal copy of DYS-HAC2 in four
clones (Appendix Table S1). Among them, clone CHO(DYS-HAC2)-7
was then selected for transfer of DYS-HAC2 into murine A9 cells, as
they have an even higher efficiency in generating microcells
compared to CHO cells. Following G418 selection, 27 A9(DYS-HAC2)
clones were randomly picked and presence of DYS-HAC2 was
confirmed by PCR in five clones. FISH analysis showed episomal
presence of DYS-HAC2 in three out of five A9(DYS-HAC2) clones
(Appendix Table S2). Figure 1F shows fluorescent in situ hybridisa-
tion (FISH) images of CHO(DYS-HAC2)-7 and A9(DYS-HAC2)-9
clones utilised as DYS-HAC2 donors in subsequent experiments.
Reversible immortalisation of DMD myoblasts enables DYS-HAC
transfer and complete genetic correction
Combined expression of hTERT and Bmi1 was shown to immor-
talise human myoblasts (Cudre-Mauroux et al, 2003). To test the
hypothesis that reversible immortalisation could extend cell prolifer-
ation enough to allow HAC transfer in human myogenic progeni-
tors, we planned to transfer the newly generated DYS-HAC2 (Fig 1)
into reversibly immortalised DMD myoblasts (riDMD myoblasts).
Before proceeding with HAC transfer, we confirmed that riDMD
myoblasts (i) contained and transcribed hTERT and Bmi1 transge-
nes (Fig EV1A), (ii) had maintained their myogenic potential
(Fig EV1B), (iii) generated dystrophin-deficient myotubes in vitro
(Fig EV1C), (iv) were not tumorigenic (N = 3; Table EV1). We then
transferred DYS-HAC2 into riDMD myoblasts via MMCT. Four
G418-resistant clones, namely riDMD(DYS-HAC2)#a, #b, #c and #d,
were selected. PCR analysis showed that two out of the four clones
were positive for all analysed HAC regions (clones #a and #d;
Fig 2A, red boxes). Parental riDMD myoblasts have a deletion from
exon 5 to exon 7 in the dystrophin gene (Fig 2B, first lane), which
would result into an out-of-frame mutation: this was indeed con-
firmed by dystrophin transcript analysis, which demonstrated an
out-of-frame mutation in riDMD myoblasts and ruled out a potential
restoration of the reading frame by skipping of exon 8 (Fig EV1D;
Muntoni et al, 1994; Cudre-Mauroux et al, 2003). Importantly, PCRs
for dystrophin exons 5, 6 and 7 after HAC transfer demonstrated
that both riDMD(DYS-HAC2)#a and #d were positive for the exons
originally deleted in the parental DMD myoblasts (Fig 2B), showing
correction of the dystrophin gene sequence. FISH and karyotype
analyses confirmed the presence of a single copy of DYS-HAC2 and
a normal karyotype (Fig 2C). Subcutaneous injection of DYS-HAC2-
corrected DMD myoblasts into immunodeficient scid/beige mice
(N = 5 per clone) did not result in tumour formation (N = 10;
Table EV1). Finally, riDMD(DYS-HAC2)#a myoblasts showed
restoration of dystrophin mRNA expression and protein production
in skeletal myotubes upon in vitro differentiation (Fig 2D–F;
detailed analysis of myogenic differentiation in Appendix Fig S1A).
hTERT and Bmi1 expression prevents replicative senescence of
human mesoangioblasts
The experimental work described so far provides proof-of principle
evidence of HAC transfer into human dystrophic myoblasts.
However, although myoblast transplantation appears to be a
promising therapeutic strategy for localised forms of muscular
dystrophy (Perie et al, 2014), it appears of limited value for wide-
spread muscle disorders such as DMD, where their modest migra-
tion potential is a major hurdle (Tedesco et al, 2010; Skuk &
Tremblay, 2014). To overcome this limitation, we extended the
DYS-HAC platform to human mesoangioblasts, which can be deliv-
ered systemically via the arterial circulation and have been recently
assessed in a phase I/II clinical trial based upon allogeneic trans-
plantation (Cossu et al, 2015). Post-natal human mesoangioblasts
are considered to be the in vitro progeny of a subset of alkaline
phosphatase (ALP)-positive skeletal muscle pericytes (Dellavalle
et al, 2007).
Firstly, human mesoangioblasts were isolated from muscle biop-
sies of three different healthy subjects (H#1, H#2 and H#3) accord-
ing to the standard protocols (Tonlorenzi et al, 2007). To exclude
myoblast cross-contamination, cells were FACS-purified as ALP-
positive/CD56-negative (see Materials and Methods). After a short
in vitro expansion, H#1, #H2 and H#3 human mesoangioblasts were
co-transduced with LOX-TERT-IRESTK and LOX-CWBmi1 lentiviral
vectors. As an additional control, cells were transduced with a LOX-
GFP-IRESTK (Fig EV2A). Phase contrast microscopy revealed that
hTERT + Bmi1 transduced polyclonal populations (Fig 3A, upper
row, right images) showed a similar morphology to their control
(CTR) counterparts (Fig 3A, upper row, left images). One polyclonal
population (hTERT + Bmi1 H#3) was then cloned by limiting dilu-
tion and three hTERT + Bmi1 clones were selected for further analy-
sis (namely H#3A, H#3B and H#3C; Fig 3A, lower row). PCR
analyses performed on genomic DNA of clonal and polyclonal popu-
lations confirmed the presence of hTERT and Bmi1 transgenes
(Fig 3B). Transcription of both transgenes was then confirmed by
RT–PCR (Fig 3C) and quantitative real-time RT–PCR analyses
(Fig 3D).
We previously reported that human mesoangioblasts show
decreased telomerase activity with prolonged passages in culture
(Dellavalle et al, 2007). In order to verify whether exogenous
expression of hTERT was sufficient to restore telomerase activity in
human mesoangioblasts as in other cell types (Weinrich et al, 1997;
Bodnar et al, 1998), a telomeric repeat amplification protocol
(TRAP) assay was performed. TRAP assay showed that all
hTERT + Bmi1 transduced clones (H#3A, H#3B and H#3C) had
detectable telomerase activity after 15 passages in culture (Fig 3E).
Telomerase activity was maintained up to at least 40 passages in
culture (Fig 3E), and all hTERT + Bmi1 clones and polyclonal popu-
lations produced more Bmi1 protein than their untransduced
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine HACs for DMD gene and cell therapy Sara Benedetti et al
4
AD
F
E
B C
Figure 2. DYS-HAC2 transfer into reversibly immortalised DMD myoblasts.
A PCR panel for HAC sequences in four neomycin-resistant riDMD(DYS-HAC2) myoblast clones. Red boxes: positive riDMD(DYS-HAC2) myoblasts.
B PCR analysis of human dystrophin exons on genomic DNA of riDMD myoblasts, riDMD(DYS-HAC2)#a and riDMD(DYS-HAC2)#d clones. Parental riDMD myoblasts:
negative control for exons 5–7; CHO(DYS-HAC2)-7: positive control.
C Left panel: karyotype analysis of riDMD myoblasts, riDMD(DYS-HAC2)#a and riDMD(DYS-HAC2)#d myoblast clones. Right panel: FISH analysis on riDMD myoblasts
and two selected riDMD(DYS-HAC2) myoblast clones (#a and #d). Insets: magnifications showing single episomal DYS-HAC2. Red/purple: rhodamine-p11-4 human
alpha satellite (centromeres of chromosome 13 and 21, hChr 13/21(cen)); green: dystrophin FITC-DMD-BAC RP11-954B16; yellow: merge. White arrowheads:
DYS-HAC2. Scale bar: 3 lm.
D RT–PCR panel for dystrophin expression in differentiated riDMD(DYS-HAC2)#a. Parental riDMD myoblasts: negative control for dystrophin (exons 5–7); healthy
myoblasts: positive control.
E Western blot for dystrophin (427 kDa) in differentiated riDMD and riDMD(DYS-HAC2)#a myoblasts; human muscle and differentiated human inducible myogenic cells
(Maffioletti et al, 2015) were used as positive control; differentiated DMD-inducible myogenic cells (Maffioletti et al, 2015) were used as negative control and myosin
heavy chain (MyHC) as normaliser (40 lg of proteins loaded for all samples but human muscle, which had 30 lg loaded).
F Immunofluorescence images showing in vitro muscle differentiation of riDMD myoblasts (negative control), riDMD(DYS-HAC2)#a and healthy donor myoblasts
(positive control). Red: MyHC; green: dystrophin; blue: Hoechst. Scale bar: 50 lm.
Source data are available online for this figure.
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counterparts (Figs 3F and EV2B). Proliferation analyses demon-
strated that hTERT and Bmi1 expression allowed human mesoan-
gioblasts to bypass replicative senescence, whereas untransduced
parental cells and GFP control clone #B5 underwent senescence
after ~15 passages in culture (Figs 3G and EV2C). Functional BrdU
incorporation assay confirmed data obtained in proliferation curves
(Figs 3H and EV2D).
Telomerase is responsible for telomere maintenance by adding
repeated telomeric sequences to prevent erosion-mediated senes-
cence (Shay & Wright, 2005). Therefore, telomere length was
measured in hTERT + Bmi1 clones by means of telomeric restriction
fragment (TRF) assay (details in Materials and Methods). As shown
in Figs 3I and EV2E, all hTERT + Bmi1 clones had stable and longer
telomeres compared to those of the control GFP-transduced clone
(GFP#B5).
We then investigated the ability of reversibly immortalised
mesoangioblasts to differentiate into multinucleated skeletal
myotubes in vitro. When cultured for 10 days under differentia-
tion-permissive conditions (details in Materials and Methods),
hTERT + Bmi1 H#1 and H#2 polyclonal populations sponta-
neously differentiate into myotubes (Fig 3J). Similarly,
hTERT + Bmi1 clones spontaneously differentiate into myotubes,
albeit at lower frequency (Fig EV2F). Previous observations lead
to the conclusion that human mesoangioblasts have a variable
myogenic potency (Bonfanti et al, 2015), which decreases with
passages in culture and which can be efficiently rescued by the
expression of the myogenesis regulator MyoD (Morosetti et al,
2006; Tedesco et al, 2011). To test whether this was also the case
for hTERT + Bmi1 clones and to minimise myogenic variability,
reversibly immortalised mesoangioblasts were transduced with a
lentiviral vector carrying the MyoD cDNA, fused with the estro-
gen receptor (ER) in order to activate its expression upon tamox-
ifen administration (MyoD-ER; Kimura et al, 2008; Tedesco et al,
2012). As a result, few days after tamoxifen activation of MyoD-
ER, reversibly immortalised human mesoangioblasts were able to
differentiate into skeletal myotubes with higher efficiency (Figs 3J
and EV2F). Taken together, these results demonstrate that expres-
sion of hTERT and Bmi1 in human mesoangioblasts enables
bypassing replicative senescence via telomere maintenance and
cell cycle progression without interfering with either spontaneous
or induced myogenic differentiation.
Immortalised human mesoangioblasts are not tumorigenic
and their immortalisation can be reverted by Cre recombinase
and ganciclovir
High proliferation rate and maintenance of telomerase expression
are associated with cell transformation (Stewart et al, 2002). To
rule out that hTERT + Bmi1-mediated immortalisation of human
mesoangioblasts could induce cell transformation and tumori-
genic conversion, cell–cell contact inhibition of proliferation and
serum/growth factor dependence were tested in vitro. In both
experimental sets, proliferation was evaluated as BrdU incorpora-
tion rate. Results showed that both clonal and polyclonal rever-
sibly immortalised mesoangioblasts were sensitive to serum and
growth factor withdrawal (Fig 4A), as well as to cell contact
inhibition of proliferation (Fig 4B), indicating that lentiviral
hTERT + Bmi1-mediated reversible immortalisation does not lead
to cell transformation. Moreover, karyotype analysis performed
on immortalised cells showed a normal diploid chromosomal
content (Fig 4C). To confirm this data, in vivo tumorigenic
assays were performed injecting clonal and polyclonal
hTERT + Bmi1 mesoangioblasts subcutaneously into immunodefi-
cient scid/beige mice (N = 4 per cell population). No tumours
developed in any of the mice injected with immortalised
mesoangioblasts after 12 months of follow-up (N = 20;
Table EV1).
Overexpression of hTERT provides extension of cell prolifera-
tion while maintaining a stable chromosomal content (Cudre-
Mauroux et al, 2003; Zhu et al, 2007; Mamchaoui et al, 2011;
Robin et al, 2015). Nonetheless, lentiviral vectors carrying the
immortalising cassette were designed to guarantee reversibility of
◀ Figure 3. Bypassing replicative senescence in human mesoangioblasts by lentiviral expression of Bmi1 and hTERT.A Upper row: phase contrast morphology of human mesoangioblasts derived from muscle biopsies of three different healthy donors (H#1, #2 and #3) before (CTR, left
images) and after lentiviral transduction with LOX-TERT-IRESTK and LOX-CWBmi1 (hTERT + Bmi1, right images). Scale bar: 100 lm. Lower row: phase contrast
morphology of three clones selected from hTERT + Bmi1 H#3 polyclonal population: H#3A, H#3B and H#3C. Scale bar: 100 lm.
B PCR on Bmi1 and hTERT transgenes. Gapdh was used as housekeeping gene.
C RT–PCR on cDNA for Bmi1 and hTERT. Gapdh was used as housekeeping gene.
D Quantitative real-time PCR analysis for hTERT and Bmi1 gene expression on untransduced (H#1, H#2 and H#3) and hTERT + Bmi1 polyclonal populations
(hTERT + Bmi1 H#1 and H#2) and clones (hTERT + Bmi1 H#3A, H#3B and H#3C). Gapdh expression was used as normaliser. Data are expressed as means  SEM
(n = 2).
E Telomeric repeat amplification protocol (TRAP) assay performed on hTERT + Bmi1 H#3A, H#3B and H#3C clones at early (E; p17, p14 and p25, respectively, for H#3A,
H#3B and H#3C) and late (L, p40) passages. HeLa cells were used as positive control (C+).
F Bmi1 protein production assessed by Western blot and relative densitometry in a polyclonal parental population (H#3) and hTERT + Bmi1 clones. Gapdh protein
used as normaliser.
G Population doubling curves of hTERT + Bmi1 H#3A, H#3B, H#3C and GFP#B5 clones. The magnification shows the growth curve from day 0 to day 55 for all
analysed clones. Data are expressed as means  SEM (n = 2).
H Bar graph showing proliferation rate of hTERT + Bmi1 clones (H#3A, H#3B and H#3C) and GFP clone (GFPB#5). Data are expressed as means  SEM (n = 3).
****P < 0.0001, one-way analysis of variance (ANOVA) with Tukey’s post hoc post-test.
I Telomeric restriction fragment (TRF) assay of hTERT + Bmi1 clones (H#3A, H#3B and H#3C) and GFP#B5 control clone at early (E; p17, p14 and p25, respectively, for
H#3A, H#3B and H#3C) and late (L; p40) passages. S: CHQ standard; M: 2.5-kb DNA ladder. Signal for GFP#B5 was weaker as fewer cells were obtained due to
reduced proliferation.
J Immunofluorescence analysis of spontaneous (left) and MyoD-ER-mediated (right) in vitro skeletal muscle differentiation of hTERT + Bmi1 polyclonal populations
H#1 and H#2. Red: myosin heavy chain (MyHC); blue: Hoechst. Scale bar: 50 lm.
Source data are available online for this figure.
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immortalisation (Salmon et al, 2000) to prevent potential adverse
events related to the reconstitution of telomerase activity and
guarantee a maximum level of safety of our platform (Bernardes
de Jesus & Blasco, 2013; Chiodi & Mondello, 2016; Terali &
Yilmazer, 2016). Firstly, loxP sites were positioned to flank
hTERT and Bmi1 cassettes, enabling Cre-mediated excision of
integrated transgenes. Secondly, hTERT and the HSV1-TK cDNAs
were connected by an internal ribosome entry site (IRES)
sequence to allow human cytomegalovirus (CMV) promoter-
mediated concomitant transcription, so that cells expressing the
A
B
C D E
Figure 4. Safety profile of reversibly immortalised human mesoangioblasts.
A In vitro serum and growth factor dependence of hTERT + Bmi1 polyclonal populations (H#1 and H#2, left graphs, n = 2 for each groups) and hTERT + Bmi1 clones
(H#3A, H#3B and H#3C, right graphs, n = 4). HeLa cells: positive control (n = 4). BrdU incorporation rate was calculated as the % of BrdU-positive cells on total
number of nuclei in 1 h time. Data plotted as means  SEM. *P = 0.0314, ***P = 0.0002, ****P < 0.0001, one-way analysis of variance (ANOVA) with Tukey’s post hoc
post-test.
B Cell contact inhibition assays of hTERT + Bmi1 polyclonal populations (H#1 and H#2, left graphs, n = 2 for each groups) and hTERT + Bmi1 clones (H#3A, H#3B and
H#3C, right graphs, n = 4). HeLa cells: positive control (n = 4). BrdU incorporation rate was calculated as the % of BrdU-positive cells on total number of nuclei. Data
plotted as means  SEM. *P = 0.0190 (HeLa, 0 vs. 4), **P = 0.0035 (H#1, 0 vs. 4), **P = 0.0020 (H#1, 0 vs. 8), ***P = 0.0003 (H#1, 0 vs. 12), ***P = 0.0006 (H#3B,
0 vs. 8), **** P < 0.0001, ns = 0.0627 (H#3B, 0 vs. 4), ns = 0.9643 (HeLa, 0 vs. 8), ns = 0.0790 (HeLa, 0 vs. 12), one-way analysis of variance (ANOVA) with Tukey’s
post hoc post-test.
C Karyotype analysis of immortalised mesoangioblast polyclonal populations.
D qRT for hTERT and Bmi1 transgenes in immortalised mesoangioblasts (H#2) 2 weeks after transduction with different multiplicity of infection (MOI 0.5, 1, 2.5, 5 and
10) of IDLV NLS-Cre. Gapdh was used as housekeeping gene. Immortalised mesoangioblasts have been used as reference (=1, black bar). Data plotted as
means  SEM (n = 2). Red box: IDLV NLS-Cre MOI 2.5 immortalised mesoangioblasts used for further experiments with ganciclovir.
E hTERT and Bmi1 PCRs on MOI 2.5 IDLV NLS-Cre-transduced immortalised mesoangioblasts treated with 10 and 20 lM ganciclovir. Positive control: untreated ()
immortalised mesoangioblasts.
Source data are available online for this figure.
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HSV1-TK would undergo apoptosis in the presence of the antiviral
drug ganciclovir (Fillat et al, 2003). Hence, cells that escape Cre-
mediated excision of the floxed hTERT or Bmi1 cDNAs will keep
transcribing the TK cDNA, thus remaining sensitive to eradication
by ganciclovir. An integrase-defective lentiviral vector expressing
a nuclear localisation signal Cre recombinase (IDLV NLS-Cre) was
then used to excise the immortalising transgenes.
To test the feasibility of the excision system, reversibly
immortalised mesoangioblasts (hTERT + Bmi1 H#2) were trans-
duced with different concentrations of IDLV NLS-Cre for 24 h
[multiplicity of infection (MOI) 0.5, 1, 2.5, 5 and 10]. Cells were
kept in culture for 2 weeks to allow dilution of excised transge-
nes, which might be otherwise detected by DNA analyses. Quan-
titative real-time PCR analysis of hTERT and Bmi1 transgenes
was performed on Cre-transduced, immortalised mesoangioblasts.
Dose-dependent reduction in both hTERT and Bmi1 was
observed in all samples transduced with IDLV NLS-Cre, ranging
from 75% (MOI 0.5) up to 99% (MOI 10; Fig 4D). These data
demonstrate that IDLV NLS-Cre recombinase efficiently excises
loxP-flanked hTERT and Bmi1 transgenes in human mesoan-
gioblasts. Similar levels of hTERT and Bmi1 transgenes excision
were confirmed by transduction of immortalised myoblasts with
IDLV NLS-Cre (Appendix Fig S1B). To investigate whether the
small percentage of cells that fail to excise the immortalising
cassettes might have a growth advantage in the absence of
ganciclovir counter-selection, we studied Bmi1 and hTERT
expression levels and cell proliferation at different time points
after IDLV NLS-Cre transduction (4, 5, 6, 7 and 8 weeks). At
4 weeks, Bmi1 and hTERT levels were raised from 5 to 6%
(MOI 2.5 IDLV NLS-Cre; Fig 4D, red box) up to 40–50% (MOI
2.5 IDLV NLS-Cre; Appendix Fig S1C) and continued to increase
up to 8 weeks, reaching the same levels of hTERT and Bmi1 as
immortalised mesoangioblasts not treated with Cre recombinase
(Appendix Fig S1C). Proliferation rate of IDLV NLS-Cre mesoan-
gioblasts at 4 weeks from IDLV NLS-Cre transduction was
lower than immortalised mesoangioblasts (42.3  2.9% vs.
33.5  1.3%), consistent with a reduction in hTERT- and Bmi1-
positive cells (Appendix Fig S1D). The decrease in proliferation
was then restored at 8 weeks after IDLV NLS-Cre (33.4  2.1%
vs. 34.4  1.3%; Appendix Fig S1D). These results showed that
in the absence of counter-selection, cells that have retained the
immortalising genes have a moderate but significant growth
advantage. As a result, we administered ganciclovir counter-
selection within 2 weeks of transduction with IDLV NLS-Cre to
eliminate cells that escaped Cre-loxP-mediated transgene excision.
As only cells carrying both immortalising transgene are able to
undergo effective immortalisation (Cudre-Mauroux et al, 2003),
the HSV1-TK cDNA was transcriptionally linked only with
hTERT using an IRES sequence; this reduced the transgene size
and the likelihood of a bystander effect elicited by a few TK-
expressing cells inducing cell death of TK-negative neighbouring
cells (Freeman et al, 1993; Denning & Pitts, 1997). For these
experiments, we selected MOI 2.5 IDLV NLS-Cre-transduced
immortalised mesoangioblasts (Fig 4D, red box), as 5–6% of
them escaped Cre-mediated hTERT and Bmi1 excision. IDLV
NLS-Cre-transduced immortalised mesoangioblasts were treated
with 10 or 20 lM ganciclovir for 3 weeks and then PCRs for
hTERT and Bmi1 transgenes were performed. As shown in
Fig 4E, IDLV NLS-Cre-transduced immortalised mesoangioblasts
were negative for both transgenes after treatment with 20 lM
ganciclovir. Taken together, these results demonstrate that
immortalisation of human mesoangioblasts with hTERT and
Bmi1 (i) does not induce cell transformation, (ii) does not lead
to tumorigenic conversion, (iii) can be safely reverted by trans-
gene excision via expression of Cre recombinase and ganciclovir
treatment.
Reversible immortalisation enables DYS-HAC-mediated genetic
correction of DMD mesoangioblasts
The above-described data demonstrate that reversible immortalisa-
tion of healthy donor human mesoangioblasts enables safe bypass-
ing of replicative senescence. The same platform was then utilised
to reversibly immortalise mesoangioblasts isolated from skeletal
muscle biopsies of DMD patients. DMD mesoangioblasts were
successfully transduced with hTERT and Bmi1 lentiviral vectors
(Fig 5A and B), showed extension of their proliferative ability
(Fig 5C), and were not tumorigenic (N = 3; Table EV1). Thus, we
used reversibly immortalised DMD (riDMD) mesoangioblasts as
recipient myogenic progenitor cells for the newly generated
▸Figure 5. Immortalisation of DMD mesoangioblasts and DYS-HAC2 transfer.A Phase contrast morphology of DMD human mesoangioblasts before (CTR) and after transduction with lentiviral vectors carrying the immortalising cDNAs
(hTERT + Bmi1). Scale bar: 100 lm.
B Bmi1 and hTERT PCRs on DMD and hTERT + Bmi1 reversibly immortalised DMD (riDMD) mesoangioblasts.
C DMD and riDMD mesoangioblasts population doubling curves. Data are expressed as means  SEM (n = 2). **P = 0.008, unpaired two-tailed t-test performed on last
time point.
D PCR analysis on riDMD(DYS-HAC2) mesoangioblasts clones obtained after MMCT. Primers were designed to analyse HAC-specific sequences (Neo and 30) and
dystrophin exons (exons 46 and 50) deleted in the DMD cells used for the study (deletion from exon 45 to 50). CHO(DYS-HAC2)-7: positive control; healthy donor
human mesoangioblasts: negative control for HAC sequences and positive control for dystrophin exons; riDMD mesoangioblasts: negative control for exons spanning
from 45 to 50. Exon 23 was used as internal control and normaliser.
E Upper panel: FISH analyses of riDMD(DYS-HAC2) mesoangioblast clones. White arrowheads and insets: single episomal copy of DYS-HAC2. Red: rhodamine-p11-4
human alpha satellite (centromeres of chromosome 13 and 21, hChr 13/21(cen)); green: dystrophin FITC-DMD-BAC RP11-954B16. Scale bar: 3 lm. Lower panel:
karyotype analysis of riDMD(DYS-HAC2) mesoangioblast clones.
F Left: bar graph showing results of in vitro transmigration assay of riDMD(DYS-HAC2) mesoangioblast clones (N = 4, n = 4), riDMD mesoangioblast parental
population (n = 4), human mesoangioblasts (n = 3) and human myoblasts (n = 3). Data plotted as means  SEM. *P = 0.0378, **P = 0.0081 [riDMD(DYS-HAC2)
clones], **P = 0.0032 (riDMD mesoangioblasts), one-way analysis of variance (ANOVA) with Tukey’s post hoc post-test. Right: fluorescence images of a riDMD
(DYS-HAC2) #B clone. Human mesoangioblasts and myoblasts were labelled with 6-carboxyfluorescein diacetate (green). Scale bar: 250 lm.
Source data are available online for this figure.
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DYS-HAC2 (Fig 1), as previously done with riDMD myoblasts
(Fig 2). Two different MMCT techniques, as well as two different
HAC donor cell types, were used [CHO(DYS-HAC2)-7 and A9(DYS-
HAC2)-9 clones, additional information in Appendix Supplementary
Methods]. Following DYS-HAC2 transfer and subsequent G418
selection, four riDMD(DYS-HAC2) mesoangioblast clones were
obtained, namely riDMD(DYS-HAC2)#A, #B, #C and #D. PCR analy-
ses of specific HAC sequences and dystrophin exons deleted in the
parental cells (from exons 45 to 50; Fig 5D) together with FISH anal-
yses (Fig 5E, upper panel), confirmed single and episomal DYS-
HAC2 presence. Additional PCRs for human (human actinin)- and
hamster-specific genes (furin and NV1) ruled out CHO contamina-
tion in the clones (Fig EV3A). Karyotype analysis showed normal
chromosomal content plus DYS-HAC2 (46 XY + DYS-HAC2; Fig 5E,
bottom panel). Tumorigenic assays in scid/beige immunodeficient
mice (N = 6–8 per cell population) showed the absence of tumour
formation and confirmed the safety profile of riDMD(DYS-HAC2)
mesoangioblasts in vivo (N = 27; Table EV1). Phase contrast
microscopy showed morphology comparable with parental cells
(Fig EV3B) and population doubling curves demonstrated mainte-
nance of proliferative potential (Fig EV3C and D). One of the key
features of mesoangioblasts is their ability to interact with endothe-
lial cells and cross the blood vessel wall when delivered systemi-
cally (Giannotta et al, 2014). To assess preservation of this
property, riDMD(DYS-HAC2) mesoangioblasts were subjected to an
in vitro transmigration assay (Giannotta et al, 2014; Bonfanti et al,
2015). Human umbilical vein endothelial cells (HUVECs) were
grown as confluent monolayers on gelatin-coated filters and fluores-
cently labelled mesoangioblasts were allowed to transmigrate for
10 h (Fig 5F). Quantification of the assay showed that riDMD(DYS-
HAC2) mesoangioblasts and the immortalised parental population
(riDMD mesoangioblasts) transmigrated to the same extent
than normal human mesoangioblasts (50.7  6.2, 55.9  9.3,
44.3  6.9 cells/mm2, respectively) and significantly more than
human myoblasts (15  1.4 cells/mm2; Fig 5F). Therefore, immor-
talisation and DYS-HAC transfer do not interfere with the migration
potential of human mesoangioblast.
Reversibly immortalised, DYS-HAC-corrected, DMD progenitors
engraft murine skeletal muscle upon transplantation
To avoid immune reaction against human cells, immunodeficient
NOD/scid/gamma (NSG) mice were first used as recipient hosts for
xenotransplantation to test survival and engraftment of reversibly
immortalised human myoblasts. NSG tibialis anterior muscles were
subjected to cryoinjury to induce regeneration and then injected
intramuscularly with 106 riDMD(DYS-HAC2) myoblasts (clone #a).
Three weeks later, muscles were collected and immunofluorescence
analysis for lamin A/C (which marks the nuclear lamina of
human donor cells) and laminin (marking extracellular matrix) on
muscle sections showed that DYS-HAC-corrected myoblasts
engrafted regenerating murine skeletal muscle and transcribed
human dystrophin from the HAC (Fig 6A). We then tested riDMD
(DYS-HAC2) mesoangioblasts in the same set-up (cryoinjured NSG
mice), injecting 106 MyoD-ER-transduced cells from clone #C. Also
in this case, muscle sections showed that DYS-HAC-corrected DMD
mesoangioblasts engrafted regenerating murine skeletal muscle
(Fig 6B and Appendix Fig S2). To further investigate the potential of
reversibly immortalised mesoangioblasts to engraft in a DMD mouse
model, dystrophic immunodeficient scid/mdx mice were used for
proof-of-principle xenotransplantation. Reversibly immortalised
MyoD-ER-transduced healthy donor mesoangioblasts (hTERT +
Bmi1 H#2) or DYS-HAC-corrected DMD mesoangioblasts [riDMD
(DYS-HAC2)#A] were injected into tibialis anterior muscles of scid/
mdx mice. Muscles were explanted after 3 weeks, and immunofluo-
rescence analyses showed the presence of dystrophin-positive
myofibres containing human lamin A/C-positive nuclei (Fig 6C and
D). Moreover, the aforementioned findings were validated perform-
ing a heterotopic transplantation assay to assess cell-autonomous
dystrophin production from donor human cells. To this aim, 106
riDMD(DYS-HAC2) myoblasts (clone #a) were injected in subcuta-
neous Matrigel plugs in NSG-immunodeficient mice [as recently
reported (Sacchetti et al, 2016)]; plugs were explanted and analysed
14 days after injection. Notably, MyHC-positive myotube-like struc-
tures double positive for lamin A/C and dystrophin were identified
in all mice, confirming dystrophin production from HAC-corrected
donor human cells (Fig 6E and Appendix Fig S3; please note that
dystrophin could only be produced by HAC-corrected cells, as no
host myofibres provided background signal). Taken together, these
results demonstrate engraftment and differentiation of DYS-HAC-
corrected DMD muscle progenitors in vivo.
Development of a next-generation, multifunctional, reversibly
immortalising DYS-HAC
Our data established feasibility and safety of the lentiviral reversibly
immortalising platform for HAC transfer in primary human muscle
progenitors. To simplify this procedure, we combined all required
gene functions into a single HAC capable of simultaneously deliver-
ing genomic integration-free reversible immortalisation, genetic
correction, inducible differentiation and controllable cell death
(Fig 7A and Appendix Fig S4). Construction of this next-generation
HAC (referred to as DYS-HAC4) involved engineering of several
sequences by gene synthesis (Fig 7A and Appendix Fig S4 for a
detailed map), including (i) the 2.4-Mb dystrophin locus for
complete genetic correction, (ii) a hTERT and Bmi1 immortalising
cassette with an elimination system via CreERT2/loxP and negative
selection by TK, (iii) a clinically tested safeguard system based upon
inducible Caspase 9 (iCasp9; Di Stasi et al, 2011), prompting apop-
tosis upon administration of the drug AP1903, (iv) an inducible
myogenic differentiation system based upon human MYOD nuclear
translocation after tamoxifen administration (MYOD-ERT2; Tedesco
et al, 2011; Maffioletti et al, 2015) to rescue myogenic capacity in
cells that might lose it after prolonged or high-density culture, (v) a
codon-optimised human dystrophin cDNA (huDYSco) under the
control of the synthetic Spc5-12 muscle-specific promoter (details in
Appendix Fig S5; Li et al, 1999; Loperfido et al, 2015) to increase
dystrophin expression, thus maximising the therapeutic effect upon
transplantation and fusion with multinucleated, dystrophin-negative
myofibres.
DYS-HAC4 was engineered with a two-step protocol by site-
specific integration of plasmids p17 and pP-DHR (Fig 7A, yellow
and blue lines, respectively) into DYS-HAC2 (Fig 1A and black line
in Fig 7A; details in Appendix Fig S4). Firstly, the p17 plasmid
carrying huDYSco and iCas9-MYOD-ERT2 cassettes was transferred
into CHO cells and integrated into DYS-HAC2 via Cre/loxP
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recombination, generating an intermediate DYS-HAC3 (Step 1,
Appendix Fig S4). The Cre-mediated recombination between the
50HPRT-lox71 site on DYS-HAC2 and the loxJTZ17-30HPRT site on
p17 resulted in HPRT gene reconstruction and HAT resistance
(Kazuki et al, 2011). DYS-HAC3-containing CHO cells were then
selected in HAT-supplemented medium. Subsequently, the pP-DHR
plasmid carrying the immortalising cassette was transferred into
CHO(DYS-HAC3) cells and integration into DYS-HAC3 was achieved
via Bxb1 attB/attP sites and the Bxb1 integrase system (Yamaguchi
et al, 2011; Step 2, Appendix Fig S4), resulting in L-histidinol dihy-
drochloride resistance gene (hisD) reconstitution (Tucker & Burke,
1996). Selection of CHO cells with recombinant DYS-HAC3 and pP-
DHR plasmid was obtained by culturing cells with L-histidinol dihy-
drochloride. Successful construction of DYS-HAC4 was then con-
firmed by PCR analysis of genomic dystrophin sequences in selected
CHO(DYS-HAC4) clones (Fig 7B–D). CHO(DYS-HAC4) clones #19
and #20 were investigated further for the presence of the novel
cassettes and CHO(DYS-HAC4) clone #19 was shown to be positive
for all relevant sequences, that is huDYSco, iCaspase9, hTERT,
Bmi1 and the recombination junction with Bxb1 integrase (Fig 7C
and D). FISH analysis of CHO(DYS-HAC4)#19 revealed that 90% of
interphase cells (n = 100) contained DYS-HAC4 and 20% meta-
phases (n = 20) maintained a single episomal copy of DYS-HAC4
(Fig 7E). Finally, RT–PCR revealed expression of all new transgenes
(Fig 7F). Detection of huDYSco expression in undifferentiated cells
could be due to interspecific issues (i.e. human sequence in hamster
background) and/or occasional leakiness of the Spc5-12 promoter in
tissues other than skeletal muscle (Rincon et al, 2015). The total
size of this novel synthetic HAC is in the range of 7 Mb.
Discussion
Here, we describe a novel stepwise strategy to enable genetic
correction of clinically relevant, human skeletal muscle-derived
progenitors for gene and cell therapy. Reversibly immortalising
lentiviral vectors proved to be safe and efficacious in extending
the proliferative capacity of DMD muscle progenitors, enabling
them to withstand transfer of a novel HAC containing the whole
dystrophin locus and the subsequent large-scale clonal cell
expansion required for bioprocessing of an advanced therapy
medicinal product. Notably, starting from a limited cell number
(3 × 104), we obtained within 31 days a number of cells poten-
tially sufficient to treat a DMD paediatric patient (in the range of
109 cells; Cossu et al, 2015). Importantly, this work has been
conducted in two independent laboratories (in the UK and in
Japan) and validated using (i) two distinct cell types, (ii) healthy
and dystrophic genotypes, (iii) five different donors, (iv) poly-
clonal and clonal analyses.
Previous work by Trono and colleagues showed that combined
expression of hTERT and Bmi1 bypassed replicative senescence in
myoblasts (Cudre-Mauroux et al, 2003). Taking advantage of the
availability of DMD immortalised myoblasts, we successfully trans-
ferred DYS-HAC2 in these cells. However, although myoblast trans-
plantation is promising for localised forms of muscular dystrophy
(Perie et al, 2014), their use in widespread muscle disorders such as
DMD is limited. Hence, we selected mesoangioblasts to take advan-
tage of their migration ability and transferred DYS-HAC2 by extend-
ing their proliferation potential using the same immortalisation
platform. hTERT-TK and Bmi1 lentiviral vectors used in this study
were originally designed to enable reversion of the immortalised
status in the presence of Cre recombinase and ganciclovir (Salmon
et al, 2000). Translation of the hTERT and Bmi1 immortalising plat-
form to DMD mesoangioblasts proved that this approach was effi-
cient at extending cell proliferation and enabled clonal DYS-HAC
transfer and subsequent amplification. The safe use of lentiviral
vectors to mediate integration and excision of the immortalising
cassettes utilised in this study is supported by recent gene therapy
clinical studies (Naldini, 2015). Additionally, our observations are
in keeping with a number of reports showing that cellular senes-
cence can be overcome by telomerase reconstitution in combination
with Bmi1 or CDK4 expression, without compromising genomic
stability, migration ability, myogenic potency or capacity to engraft
skeletal muscle (Cudre-Mauroux et al, 2003; Zhu et al, 2007; Shiomi
et al, 2011; Robin et al, 2015). Even though we did not observe
Pax7 expression in immortalised cells, it is unlikely that
◀ Figure 6. Transplantation of reversibly immortalised human muscle progenitors in immunodeficient mice.A Immunofluorescence images (representative) showing donor-derived lamin A/C-positive nuclei (red) in a cryoinjured tibialis anterior muscle of an NSG mouse after
intramuscular injection of 106 riDMD(DYS-HAC2) myoblasts (clone #a). Green: laminin; blue: Hoechst. Scale bar: 100 lm. Right panel: RT–PCR analysis of the same
transplanted muscles showing human dystrophin mRNA expression in the tibialis anterior (TA) muscles of four NSG mice (human muscle: positive control;
untransplanted TA: negative control).
B Immunofluorescence images showing donor-derived lamin A/C-positive nuclei (red) in a cryoinjured tibialis anterior muscle of an NSG mouse after intramuscular
injection of 106 MyoD-ER-transduced riDMD(DYS-HAC2) mesoangioblasts [riDMD(DYS-HAC2)#C]. Green: laminin; blue: Hoechst. White arrowheads: human lamin
A/C-positive nuclei. Scale bars: 75 lm. Right bar graph: quantification of lamin A/C-positive nuclei in the same experiment. Data plotted as means  SEM (N = 3;
additional information in Appendix Fig S2).
C Immunofluorescence of frozen section of a scid/mdx mouse tibialis anterior muscle upon intramuscular injection with 106 MyoD-ER-transduced healthy donor
immortalised mesoangioblasts (hTERT + Bmi1 H#2). Red: lamin A/C and dystrophin; green: laminin; blue: Hoechst. Scale bars: 50 lm.
D Immunofluorescence on a frozen section of a scid/mdx mouse tibialis anterior muscle upon intramuscular injection with 106 MyoD-ER-transduced riDMD(DYS-HAC2)
mesoangioblasts [riDMD(DYS-HAC2)#A]. IM: intramuscular. Red: lamin A/C and dystrophin; blue: Hoechst. Scale bars: 50 lm.
E Heterotopic subcutaneous transplantation assay. Upper panel: confocal microscopy pictures showing a representative myosin heavy chain (MyHC)-positive (green),
myotube-like structure containing human lamin A/C-positive nuclei (red) upon immunofluorescence staining of Matrigel plugs (106 cells were injected
subcutaneously 2 weeks earlier in four immunodeficient NSG mice; arrowheads highlight multinucleation). Lower panel: confocal microscopy pictures showing
another representative myotube-like structure from the same experiment immunostained positively for both lamin A/C (red) and dystrophin (green). Arrowheads
highlight dystrophin staining pattern. Bar graphs quantify respective panels. Four mice were transplanted, all showed engraftment, and Matrigel plugs from three
randomly selected animals were quantified. A minimum of 130 human nuclei per plug were counted (in nine randomly selected high-power fields). Data plotted as
means  SEM (N = 3). Additional details in Appendix Fig S3. Scale bar: 15 lm.
Source data are available online for this figure.
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immortalising vectors caused this, as Bmi1 plays a key role in
supporting skeletal muscle regeneration and maintaining the satel-
lite cell pool (Robson et al, 2011; Di Foggia et al, 2014; Dibenedetto
et al, 2017). This might be due to extensive passaging in vitro or to
the amplification of cells that might have already lost Pax7 expres-
sion during the initial expansion pre-transduction. Recent advances
in human satellite cell purification (Xu et al, 2015) together with
immortalisation at early passages could improve this outcome. The
same process could be less relevant for human mesoangioblasts,
whose dependence on Pax7 is unclear. Variability of myogenic
capacity could also be a consequence of high-density cultures during
the MMCT technique necessary for HAC transfer. In this event, a
contingency plan with MyoD-ER-induced rescue of differentiation
has been described here.
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In this work, we have also advanced chromosome engineering
for ex vivo gene therapies. We firstly generated a novel DYS-HAC,
namely DYS-HAC2, devoid of potentially immunogenic genes and
therefore one step closer to a possible clinical-grade product
compared to the previous DYS-HAC (Hoshiya et al, 2009). Addition-
ally, we have developed a next-generation HAC capable of deliver-
ing genomic integration-free reversible immortalisation, genetic
correction, additional dystrophin expression, inducible differentia-
tion and controllable cell death—all simultaneously in an episomal
vector. To our knowledge, this novel HAC represents the largest and
possibly most complex gene therapy vector developed to date:
future studies will assess its function in vitro and in vivo after trans-
fer into different human myogenic cells, including timing and
dynamics of clonal HAC-mediated immortalisation in primary cells.
Alternative mutation-specific strategies are currently being
developed for DMD (Foster et al, 2012; Bengtsson et al, 2016).
Among these, antisense oligonucleotide-mediated exon skipping
appears promising and ataluren has recently received market
authorisation for nonsense mutations; nonetheless, recent clinical
trials highlight the need for further studies to clarify clinical effi-
cacy (Lu et al, 2014; Voit et al, 2014; Godfrey et al, 2017;
McDonald et al, 2017). However, these strategies cannot be
applied to a significant number of DMD mutations in functional
domains or to large deletions (Aartsma-Rus et al, 2009). “Perma-
nent” exon skipping via adeno-associated viral vector (AAV)-
mediated gene editing also appears to be a promising option
(Long et al, 2016; Nelson et al, 2016; Tabebordbar et al, 2016;
Young et al, 2016); however, immune reactions against AAVs
(Boisgerault & Mingozzi, 2015) and the editing enzyme (which
usually is of prokaryotic origin) plus off-target effects might delay
clinical translation. Although recent work provides encouraging
in vitro evidence of lentiviral full-length dystrophin transfer into
human myoblasts (Counsell et al, 2017), HAC-mediated gene ther-
apy offers the chance to cover the entire spectrum of DMD muta-
tions while preserving all the complex dystrophin regulatory
elements (Muntoni et al, 2003). Additionally, safety profile and
standard operating procedures for manufacturing both cell popula-
tions used in this study have been already developed in allo-
geneic and autologous clinical-grade conditions (Perie et al, 2014;
Cossu et al, 2015), thus paving the way for future clinical transla-
tion of genetically corrected cells.
Although iPS cell-derived myogenic progenitors promise to
overcome some of the hurdles of cell therapy for muscle disor-
ders (reviewed in Loperfido et al, 2015), they are in very early
and critical stage of pre-clinical translation: safety concerns will
need to be fully addressed before usage in clinical settings
requiring systemic or multiple administrations such as in DMD.
Importantly, clinical translation of iPS cell-derived progenitors
(e.g. Chal et al, 2015; Choi et al, 2016; Darabi et al, 2012;
Loperfido et al, 2015; Tedesco et al, 2012) is likely to rely on
prior successful clinical studies with their tissue-derived counter-
parts and technologies such as the one described here are likely
to benefit this critical step.
Overall, we expect the translational journey of HAC-based cell
therapy to be complex, but no more challenging than those of
other gene therapy vectors (Tedesco, 2015). However, some
hurdles still need to be overcome, such as the low efficiency of
HAC transfer to recipient cells: new technologies to improve this
aspect have been recently developed and are currently under
investigation in our laboratories (Hiratsuka et al, 2015; Suzuki
et al, 2016). Lastly, as much as DMD gene therapy relies on
size/complexity of the dystrophin copy delivered to dystrophic
cells, efficacy of cell therapy for DMD is linked to the amount
of stem/progenitor cells able to reach and engraft the dystrophic
muscles and their myogenic potency. Although we provided
proof-of-principle evidence of engraftment and differentiation of
HAC-corrected human progenitors in vivo (Fig 6), transplantation
protocols will require optimisation to reach clinical efficacy.
Recent work by our laboratories and others showed that it is
possible to increase cell engraftment with consequent functional
amelioration of the dystrophic phenotype (Hindi et al, 2013;
Giannotta et al, 2014). Combination of these approaches (e.g.
improvement of HAC transfer efficiency and augmented cell
engraftment) could bring the DYS-HAC platform closer to clinical
translation, although specific studies in small and large animal
models will be required to define the extent of its safety and
efficacy in vivo.
Taken together, this work provides the first evidence of
HAC transfer into clinically relevant, dystrophic human muscle
progenitors and describes the development of next-generation
multifunctional artificial chromosomes for ex vivo gene
therapy.
◀ Figure 7. Generation of a novel, synthetic, multifunctional DYS-HAC.A Schematic diagram of DYS-HAC4, generated by integration of plasmids p17 (yellow line) and pP-DHR (blue line) into DYS-HAC2 (Fig 1A) as shown
also in Appendix Fig S4. Four functional cassettes are present: (i) dystrophin locus (2.4 Mb) for complete genetic correction, (ii) hTERT and Bmi1
immortalising cassette under control of MA1 bidirectional promoter (Amendola et al, 2005) and floxed by loxP sites to be eliminated via Cre-loxP
recombination system. Excision of the immortalising cassette is monitored by EGFP expression, response to blasticidin (Bsd) resistance and sensitivity
to ganciclovir (TK), (iii) codon-optimised human dystrophin (huDYSco, 11.1 kb) under control of the Spc5-12 promoter to increase dystrophin
expression, (iv) inducible Caspase 9 (iCas9) and human MYOD-ERT2 under a PGK promoter for controllable cell death and myogenic differentiation,
respectively.
B PCR analyses of selected CHO(DYS-HAC4) clones confirming the presence of DNA sequences derived from DYS-HAC2 (DYS-HAC backbone detected with 30 , Puro and
Sk23/DMD5t primers, Cre-lox71/loxJTZ17 recombination detected with HPRT primers, genomic dystrophin sequence detected using DYS5L/5R, DYS6L/6R DYS7L/7R
and DYS8L/8R primers).
C, D PCR analyses of CHO(DYS-HAC4) clones #19 and #20 showing the presence of all relevant novel sequences confirming insertion of plasmid p17 and pP-DHR.
E FISH analysis of CHO(DYS-HAC4) clone #19 showing episomal presence of DYS-HAC4 in single copy (red: rhodamine-human COT-1 DNA; green: FITC-Plasmid
pP-DHR containing the immortalising cassette. Scale bar: 5 lm.
F RT–PCR analysis showing expression of huDYSco, immortalising cassette (hTERT and Bmi1), MYOD-ERT2 and iCaspase 9 in CHO(DYS-HAC4) clone #19. For all PCRs,
CHO-K1 cells were used as negative control and CHO(DYS-HAC4) parental population as positive control.
Source data are available online for this figure.
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Materials and Methods
Cell isolation and culture
Primary cells were isolated from human healthy donor and DMD
skeletal muscle biopsies as previously described (Tonlorenzi et al,
2007). Cells were subsequently harvested, suspended in 1% FBS,
2 mM EDTA PBS and incubated with CD56-PE (NCAM; Miltenyi
Biotec) and ALP-FITC (Santa Cruz) antibodies for 30 min at 4°C.
Human mesoangioblasts were isolated as alkaline phosphatase
(ALP)-positive/CD56-negative fraction (Dellavalle et al, 2007) via
FACS (DIVA Vantage, BD) and cultured in MegaCell Dulbecco’s
modified Eagle’s medium (MegaCell DMEM, Sigma) containing 5%
foetal bovine serum (FBS; Life Technologies), 2 mM glutamine,
penicillin and streptomycin (100 IU + 0.1 mg/ml; Sigma), 1% non-
essential amino acids (Sigma), 0.05 mM 2-mercaptoethanol (Gibco),
5 ng/ml of HGF (Sigma) and human basic FGF (Gibco). For in vitro
skeletal muscle differentiation, human mesoangioblasts were plated
on Matrigel-coated dishes, and once confluent, they were switched
from MegaCell medium to DMEM (Sigma) 2% horse serum (Euro-
clone) plus 1% glutamine (Sigma), 1% penicillin/streptomycin
(Sigma) and cultured for an additional 7–10 days before analysis.
For MyoD-ER-induced differentiation of human mesoangioblasts
and myoblasts previously transduced with tamoxifen-inducible
MyoD-ER lentiviral vector, 4 OH-tamoxifen was added to culture
medium following the previously published protocols (Gerli et al,
2014). Specific tamoxifen concentration and duration of pulse
requires cell line-specific titration for optimal results.
Chicken DT40(DYS-HAC2) cells were maintained at 40°C in RPMI
(Sigma) medium supplemented with 10% foetal bovine serum
(FBS), 1% chicken serum, 50 lm 2-mercaptoethanol, 1% glutamine
and 1% penicillin/streptomycin plus 1.5 mg/ml G418 (neomycin,
Sigma). CHO(DYS-HAC2) cells were cultured in Ham’s F-12 nutrient
mixture (Sigma) with 10% FBS, 1% glutamine, 1% penicillin/strep-
tomycin and 0.8 mg/ml G418. A9(DYS-HAC2) cells were maintained
in DMEM plus 10% FBS, 1% glutamine, 1% penicillin/streptomycin
and 0.8 mg/ml G418. riDMD(DYS-HAC2) clones were selected with
the addition of G418 to the culture medium (0.5 mg/ml for mesoan-
gioblasts clones; 0.6 mg/ml for myoblasts clones). HeLa cells were
kept in DMEM supplemented with 10% FBS, 1% glutamine and 1%
penicillin/streptomycin. HUVECs were cultured in EGM media
(Lonza) in 5% CO2/3% O2 at 37°C on 1.5% gelatin-coated plastic.
riDMD myoblasts were cultured in Iscove’s modified Dulbecco’s
medium (IMDM; Sigma) containing 10% FBS, 2 mM glutamine,
0.1 mM 2-mercaptoethanol, 1% non-essential amino acids, human
basic fibroblast growth factor (5 ng/ml), HGF (5 ng/ml; Sigma),
penicillin (100 IU/ml), streptomycin (100 mg/ml), 0.5 mM oleic and
linoleic acids (Sigma), 1.5 mM Fe2+ [iron(II) chloride tetrahydrate,
Sigma; or Fer-In-Sol, Mead Johnson], 0.12 mM Fe3+ [iron(III) nitrate
nonahydrate, Sigma; or Ferlixit, Aventis] and 1% insulin/transferrin/
selenium (Gibco). Colcemid treatment varied according to purpose
(MMCT or FISH) and cell type, as detailed in Appendix Table S3.
Lentiviral vectors
LOX-TERT-IRESTK (human TERT), LOX-GFP-IRESTK, LOX-CWBmi1
(murine Bmi1, 92.4 and 98% degree of homology with human
cDNA and protein, respectively; Alkema et al, 1993; Bhattacharya
et al, 2015), IDLV NLS-Cre and MyoD-ER (murine MyoD) lentiviral
particles were generated and titrated as previously published
(Messina et al, 2010). LOX-TERT-IRESTK, LOX-GFP-IRESTK, LOX-
CWBmi1 plasmid maps and sequences are available at www.addge
ne.org/Didier_Trono/. For IDLV NLS-Cre infection, cells were
transduced for 24 h. For all other lentiviruses, cells were trans-
duced overnight. All transductions were performed with polybrene
(8 lg/ml).
Telomeric repeat amplification protocol (TRAP) assay
Detection of telomerase activity was done using TRAPeze Telom-
erase Detection Kit (Chemicon) following the manufacturer’s
instructions. Cells were collected and proteins were extracted using
1× CHAPS lysis buffer incubating each sample at 30°C for 30 min,
allowing telomerase (if present and active) to add six bases telom-
eric repeats onto 30 end of a synthetic oligonucleotide substrate.
Lysates were then amplified using PCR generating a ladder of prod-
ucts with six base increments starting at 50 nucleotides in presence
of c-32P-ATP end-labelled primers. PCR products were then run on a
non-denaturing polyacrylamide gel, and then, the gel was then
directly exposed on X-ray films.
Immunofluorescence
Immunofluorescence analysis was performed as previously published
(Tedesco et al, 2012). Briefly, muscle samples were frozen in liquid
nitrogen–cooled isopentane and serial 7-lm sections were cut using a
cryostat (Leica). Cells or tissue sections were washed with PBS and
fixed with 4% PFA (Sigma) at 4°C for 10 min, permeabilised with
0.2% Triton X-100 (Sigma) and 1% BSA (Sigma) in PBS for 30 min
at room temperature (RT). Cells/tissue sections were then blocked
with 10% donkey and/or goat serum (Sigma) for 30 min at room
temperature to reduce secondary antibody background signal. Tissue
sections were incubated overnight at 4°C with primary antibodies
(list available in Appendix Table S4; sections were not fixed for
dystrophin staining). After incubation, samples were washed with
0.2% Triton X-100, 1% BSA in PBS and then incubated with 488,
546, 594 or 647 fluorochrome-conjugated IgGs (Molecular Probes)
together with Hoechst dye for 1 h at room temperature in 0.2%
Triton X-100/PBS. After three final washes in PBS, dishes or slides
were mounted using mounting medium (Dako) and analysed under
fluorescence microscopes (Nikon and Leica). Images were analysed
using either ImageJ or Photoshop (CS4 or CC; Adobe).
Western blot
For detecting Bmi1, proteins were extracted using Laemmli buffer
with 2% sodium dodecyl sulphate (SDS), 50 mM Tris–HCl pH 6.8
and 10% glycerol. For dystrophin detection, proteins were extracted
using 3% SDS, 0.115 M sucrose and 0.066 M Tris–HCl pH 7.5
buffer. Lysates were then incubated on a running wheel at 4°C for
1 h and then centrifuged at 15,000 g for 15 min. Protein concentra-
tions were determined by BCA protein assay (Pierce) using bovine
serum albumin for standard curve; 0.1 mM DTT (dithiothreitol) was
added after determination. Before loading, samples were denatured
at 90°C for 5 min or 70°C for 10 min. In the case of Bmi1, 50 lg of
proteins was loaded and separated on 8% polyacrylamide gel, while
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for dystrophin 30–40 lg of proteins was loaded and separated on a
7.5% polyacrylamide gel. Run was monitored by using dual colour
Standards (Bio-Rad). Proteins were then transferred using iBlot Gel
Transfer device (Invitrogen) according to the manufacturer’s
instructions, saturated with 5% milk in 0.1% Tween-20 (Sigma)–
TBS buffer and hybridised overnight at 4°C with mouse anti-Bmi1
(Millipore) or mouse anti-dystrophin MANDYS106 (Nguyen &
Morris, 1993) antibodies. Mouse anti-GAPDH (Sigma) or MyHC
(Developmental Studies Hybridoma Bank) was used as normalisers.
Membranes were then washed four times (10 min each) with 0.1%
Tween-20 (Sigma)–TBS buffer and incubated with HRP-conjugated
IgGs (Amersham; 1:10,000 dilution) for 1 h at room temperature,
washed four times and finally visualised with the ECL immunoblot-
ting detection system (Amersham). Please refer to Appendix Table S4
for a list of all antibodies used for Western blot.
PCR and quantitative real-time (qRT) PCR analyses
DNA and RNA were extracted with DNeasy Blood and Tissue kit
(QIAGEN) and RNeasy mini kit (QIAGEN), respectively. RNA was
reverse-transcribed into double-strand cDNA using ImPromTM-II
Reverse Transcription System (Promega). Bio-Rad CFX96 thermocy-
cler was used for quantitative real-time analysis, and fold change in
gene expression was calculated using ΔΔCt method (fold
change = 2DDCt ). The complete list of primer sequences and PCR
products is available in Appendix Tables S5 and S7.
In vitro cell proliferation assays
For BrdU incorporation assay, 8 × 104 human mesoangioblasts were
seeded in 3.5-cm dishes to test baseline cell proliferation. The day
after plating, 50 lM BrdU (Sigma) was added to the culture medium
and cells were kept in the incubator for 1 h. Cells were then washed
twice with PBS, fixed with 95% ethanol–5% acetic acid solution for
20 min, incubated for 10 min with 1.5 M HCl and permeabilised for
5 min with 0.2% Triton in PBS. Immunofluorescence staining was
performed using Anti-BrdU detection kit (Amersham), and nuclei
were stained with Hoechst. BrdU+ and Hoechst+ cells were counted
using fluorescence microscopy. Proliferation rate was calculated as
the percentage of BrdU+ cells on the total number of nuclei
(Hoechst+ cells). BrdU incorporation (1 h pulse) was used also for
serum/growth factor dependence and cell contact inhibition assays.
For each set of experiments and time points (baseline, days 4, 8 and
12), 8 × 104 cells were seeded. In the case of serum/growth factor
dependence assay, cells were cultured in DMEM plus 2% horse
serum, 1% glutamine and 1% penicillin/streptomycin from 24 h
after initial seeding. BrdU incorporation was performed at days 4, 8
and 12 in growth factor and serum-free media. In the case of cell
contact inhibition assay, cells were allowed to reach confluence and
BrdU incorporation rate was tested at days 4, 8 and 12. HeLa cells
were used as positive control.
Population doubling curves were calculated as previously
described (Cudre-Mauroux et al, 2003). Briefly, once cells reached
optimal confluence (70–80%), they were detached with trypsin,
collected, counted and re-seeded. Growth curves were obtained
by calculating the number of population doublings (PD) as a prolif-
eration index. PD = logN/log2; N = cells collected/cells initially
plated.
Telomere restriction fragment (TRF) assay
DNA was extracted from cells using the Blood & Cell Culture DNA
Mini kit (Qiagen), and TRF assay was performed with TeloTAGGG
Telomere Length Assay Kit (Roche) according to the manufacturer’s
instructions. Briefly, genomic DNA was digested using restriction
enzymes HinfI and RsaI, which ensure that telomeric and/or sub-
telomeric DNA is not cut, while non-telomeric DNA is digested to
give rise to low molecular weight fragments. Genomic fragments
were separated on a 0.8% agarose gel and transferred by capillarity
to a nylon membrane. A digoxigenin (DIG)-labelled probe specific
for telomeric repeats was used and membranes were incubated with
a DIG-specific antibody covalently coupled to alkaline phosphate.
Alkaline phosphatase metabolises CDP-Star, a highly sensitive
chemiluminescent substrate that the membrane has been incubated
with; as a result, visible signals indicate telomere probe and hence
the telomeric restriction fragment (TRF) location on the blot. The
average TRF length can be determined by comparing the location of
the TRF on the blot relative to a molecular weight.
Microcell-mediated chromosome transfer
CHO(DYS-HAC), A9(DYS-HAC), riDMD(DYS-HAC2) mesoan-
gioblasts and riDMD(DYS-HAC2) myoblasts hybrids were generated
by microcell-mediated chromosome transfer (MMCT) as previously
described (Koi et al, 1989; Katoh et al, 2010; Kazuki et al, 2010;
Hiratsuka et al, 2015). Detailed protocols can be found in
Appendix Supplementary Methods.
DNA construction and HAC engineering
The targeting vector pN for generation of the DYS-HAC2 was
constructed in the pBSII backbone vector (Stratagene) using stan-
dard ligation technique. The pN contains (i) 3.8- and 2.6-kb frag-
ments for homologous arms corresponding to human chromosome
21 and X locus in AL050305 and AP001657, respectively, (ii) 50
HPRT gene, (iii) lox71 site, and (iv) CMV promoter-driven
neomycin gene flanked by FRT sites. Further details on construction
of pN are available upon request. The plasmid pCAG-T7-F encodes
the F protein of the Edmonston-B strain under the control of CAG
promoter (Katoh et al, 2010). The plasmid pTNH6-H-CD13 encodes
H protein, the fusion protein of the measles virus and anti-CD13-
scFV under the control of CMV promoter in order to re-target the
fusogenic activity of the H protein (Hiratsuka et al, 2015). The DNA
sequence encoding for anti-CD13-scFv was flanked by 50-SfiI recog-
nition site and 30-NotI recognition site, synthesised (Blue Heron)
and subcloned into pUCminusMCS plasmid (Invitrogen). The SfiI/
NotI fragment was subcloned into pTNH6-H at the corresponding
restriction sites, resulting in pTNH6-H-CD13. The ORF correspond-
ing to the scFv peptide is in uppercase.
ScFv recognising CD13: gcggcccagccggccGACTACAAGGACGTG
GTCATGACTCAGACACCACTGAGCCTGCCCGTTTCCCTCGGCGACC
AGGCCAGCATATCATGCCGGAGTTCTCAGTCCATCGTTCACTCAA
ACGGCAATACCTATCTGGAATGGTATCTTCAGAAGCCGGGTCAGT
CCCCTAAGCTCCTGATCTACAAGGTGTCAAACAGATTTTCAGGAG
TGCCCGACAGATTCTCCGGTAGCGGGTCTGGCACAGATTTCACCC
TTAAGATTAGCAGAGTCGAGGCAGAGGACCTGGGCGTTTACTAC
TGCTTTCAGGGGTCTCACGTGCCTTGGACCTTTGGTGGGGGTACGA
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AACTGGAAATCAAACGCGGCGGGGGAGGGAGCGGAGGGGGCGGT
TCAGGTGGTGGCGGGTCCGGTGGGGGCGGCAGTCAAGTTCAGCTG
CAACAGTCTGGCGCTGAATTGATGAAACCAGGAGCCAGCGTTAAG
ATCAGCTGTAAGGCGACTGGATACACCTTTAACTCTTACTGGATCG
AATGGGTGAAGCAGCGCCCAGGCCACGGCCTGGAGTGGATCGGAG
AGATCCTCCCAGGCAGCGGGTCTACTAACTACAACGAGAAATTCA
ATGGGAAGGCCACTTTTACAGCAGATGCGTCATCTAACACAGCCT
ATATGCAGCTGTCCTCTCTCACAAGTGAGGATAGCGCCGTGTATT
ATTGTGCGCGCGTGTATTATGGGACATATGGCAGGGTGTATTGGG
GCCAGGGCACGACACTGACTGTCAGTAGTGCTTCTGGCGCAGATg
cggccgcatgatagtaagcggcccagccggcc.
The plasmid pTNH6-Haa-EGFR encodes the fusion protein of the
measles H protein and anti-EGFR-scFV under the control of CMV
promoter (Nakamura, unpublished). The blasticidin expression
plasmid pCMV/Bsd was purchased from Life Technologies.
Synthesis of p17 and pP-DHR plasmids
p17 and pP plasmids were synthesised by Life Technologies after
careful in-house designing. Plasmid pP was then modified with FseI
digestion and self-ligation with the FseI sites to remove HR sequence
(homologous recombination arm for gene insertion in DT40 cells;
Hoshiya et al, 2009; Kazuki et al, 2011) in order to shorten pP plas-
mid and increase efficiency of transfection in target CHO cells.
DNA transfection
DNA transfection for DYS-HAC2 generation
The DYS-HAC1 was previously developed by a cloning of the entire
human dystrophin gene into the HAC backbone named 21HAC2
using Cre/loxP-mediated targeted translocation in CHO cells
(Hoshiya et al, 2009; Kazuki et al, 2010). DT40 hybrid cells contain-
ing the DYS-HAC1 were established by MMCT from CHO hybrids
containing the DYS-HAC1 and maintained with 1.5 mg/ml G418
(Invitrogen). The DT40 hybrid cells retaining the DYS-HAC1 were
transfected by the electroporation of 1 × 107 cells with 25 lg of the
NotI-linearised pN vector at 25 lF and 550 V in a 4-mm cuvette
using a Gene Pulser (Bio-Rad, Hercules, CA, USA). The cells were
suspended in basic growth medium and aliquoted into four 96-well
flat-bottomed microtiter plates (Becton–Dickinson, Franklin Lakes,
NJ, USA). After 2 days, the cells were suspended in selective
medium with 1.5 mg/ml G418. About 14 days later, drug-resistant
colonies were picked up and expanded for the following analyses.
DNA transfection for MMCT using measles virus fusogenic envelope
proteins (unconventional MMCT)
1.5 × 107 CHO(DYS-HAC2) cells were prepared in 10-cm dishes and
then co-transfected with 12 lg of pTNH6-H-CD13 and pCAG-T7-F,
respectively, using Lipofectamine 2000 (Invitrogen). 24 h after
transfection, transfected CHO(DYS-HAC2) cells were expanded for
MMCT experiments.
DNA transfection for DYS-HAC3 and DYS-HAC4 generation
2 × 106 CHO(DYS-HAC2) cells were co-transfected with p17 (8 lg)
and Cre-expressing plasmids (1 lg) using Lipofectamine 2000 (Invit-
rogen) to induce insertion of p17 into DYS-HAC2 via Cre/LoxP
system and generate DYS-HAC3. 24 h after transfection, CHO cells
were expanded with a hypoxanthine–aminopterin–thymidine
(HAT)-supplemented medium (Sigma-Aldrich) to select only CHO
cells containing DYS-HAC3. CHO(DYS-HAC3) cells were further
transfected with pP-DHR and Bxb1-expressing plasmid following the
same protocol detailed above. Selection was performed according to
the following: 8 lg of blasticidin S (Wako), 800 lg of G418
(Promega), 7 mM of L-histidinol dihydrochloride (Sigma-Aldrich)
and HAT medium.
In vitro migration assay
In vitro migration assays were performed using human umbilical
vein endothelial cells (HUVECs) as previously published (Giannotta
et al, 2014; Bonfanti et al, 2015). Culture inserts (Corning) were
incubated for 1 h at 37°C with 1.5% (w/v) gelatin and cross-linked
with 2% (w/v) glutaraldehyde solution (Sigma-Aldrich) at room
temperature. After 15 min, glutaraldehyde was removed and inserts
were incubated with 70% ethanol (v/v) for 1 h, then washed five
times with sterile PBS and incubated overnight with PBS containing
2 mM glycine. HUVECs were then plated in 5% CO2/3% O2 at 37°C
to reach confluence. Human mesoangioblasts were detached with
PBS/1 mM EDTA and labelled with 0.7 lM 6-carboxyfluorescein
diacetate (6-CFDA; Molecular Probes, Invitrogen) in suspension for
30 min at 37°C in serum-free media. 105 fluorescent human cells
per insert were added to the upper chamber in serum-free MegaCell
and were left to migrate in 5% CO2/3% O2 at 37°C for 10 h. After
fixing both lower and upper chamber for 10 min with 4%
paraformaldehyde, the non-migrated cells on the upper face of the
filters were scraped away using a cotton bud, retaining only the cells
that had migrated through the HUVEC monolayer. Five pictures for
each filter were taken using an inverted fluorescence microscope
(Leica), migrated cells on the lower surface were counted and data
displayed as numbers of migrated cells per mm2.
Chromosome analyses (karyotype and fluorescence in situ
hybridisation)
Karyotype analyses were performed using either fixed metaphase or
interphase spreads stained with quinacrine mustard and Hoechst
33258 to enumerate chromosomes. Images were captured using an
AxioImagerZ2 fluorescence microscope (Carl Zeiss GmbH).
For fluorescence in situ hybridisation (FISH), cells were incu-
bated overnight with colcemid (Sigma) to obtain metaphase spreads.
Following colcemid treatment, cells were trypsinised, collected, incu-
bated with 0.075 M KCl and washed three times with fresh-made
Carnoy’s solution (3 parts of methanol, 1 part of acetic acid). Cells
were then re-suspended in Carnoy’s solution and approximately one
drop of cell suspension was spread on each microscope slide [pre-
incubated in 50% (v/v) ethanol]. Cells were fixed on microscope
slides with a Bunsen’s burner and stored for up to a week at 80°C.
FISH analyses were performed using either fixed metaphase or
interphase spreads of each cell hybrid. Digoxigenin-labelled (Roche)
human COT-1 DNA (Invitrogen) and biotin-labelled BAC DNA
RP11-954B16 (located in the Dystrophin genomic region, Children’s
Hospital Oakland Research Institute) were used for the detection
of DYS-HAC2 in DT40 (DYS-HAC2), A9(DYS-HAC2)-9 and CHO
(DYS-HAC2)-7 cells. Digoxigenin-labelled p11-4 human alpha
satellite (centromeres of chromosome 13 and 21, hChr 13/21(cen))
and biotin-labelled RP11-954B16 were used for the detection
of DYS-HAC2 in riDMD(DYS-HAC2) clones. Digoxigenin-labelled
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human COT-1 DNA and biotin-labelled plasmid pP-DHR (immortalis-
ing cassette) were used for the detection of DYS-HAC4 in CHO(DYS-
HAC4)#19 clone. Digoxigenin-labelled probes were combined with
anti-digoxigenin-rhodamine (red)while biotin-labeled probe were
combined with anti-biotin-FITC (green). Chromosomal DNA was
counterstained with 40,6-diamidino-2-phenylindole (DAPI, Sigma) or
with Giemsa staining, and images were captured using a Leica (Ger-
many) DMI6000B microscope equipped with an AF6000 system and
LAS AF 2.3.5 software or AxioImagerZ2 fluorescence microscope
(Carl Zeiss GmbH). Additional information is given in Appendix
Supplementary Methods.
Mice and in vivo experiments
Scid/mdx (C57BL/6 background) and scid/beige mice were geno-
typed as previously described (Tedesco et al, 2011, 2012). NSG mice
were kindly provided by UCL Biological Services. All mice were kept
in specific pathogen-free (SPF) environment, and all the procedures
involving living animals are conformed to Italian (D.L.vo 116/92
and subsequent additions) and English law (Animals Scientific
Procedure Act 1986 and subsequent additions) and were approved
by both San Raffaele Institutional Review Board (IACUC 355) and
UK Home Office (Project Licences no. 70/7435 and 70/8566).
For tumorigenesis experiments, both adult (between 2 and
6 months of age) female and male scid/beige immunodeficient mice
were subcutaneously injected in the dorsal flank with 2 × 106 cells
in 200 ll of PBS (without calcium and magnesium) containing 0.2
international units of sodium heparin (Mayne Pharma). Mice were
then regularly examined to detect tumour formation or any signs of
distress. Specific follow-up times and the number of mice used are
indicated in the respective figure legends or result sections. HeLa
cells were used as positive control.
For intramuscular cell transplantation experiments, 2-week-old
immunodeficient dystrophic scid/mdx and 3-month-old immunode-
ficient NOD/scid/gamma (NSG) male mice were used. In the case of
NSG mice, tibialis anterior muscles were subjected to cryoinjury
before cell injection as described previously (Meng et al, 2015) to
promote muscle regeneration. The day before transplantation,
MyoD-ER transduced cells were activated with 1 lM 4 OH-tamox-
ifen. Accordingly, tamoxifen (33 lg/g) was given to mice once per
day subcutaneously for three consecutive days starting from 1 day
prior to transplantation. Before intramuscular injections, cells were
trypsinised, counted, washed/centrifuged twice in PBS and
suspended in PBS at the concentration of 5 × 104 cells/ll. 20 ll of
cell suspension (equivalent to 106 cells) was injected in selected
hind limb muscles (tibialis anterior for NSG mice; tibialis and
gastrocnemius for scid/mdx mice). Hind limb muscles from the
same mouse were used as contralateral control and injected with
20 ll of PBS. Mice were humanely killed 3 weeks after transplanta-
tion and muscles explanted for further analyses. For a detailed
protocol, see Gerli et al (2014).
For heterotopic subcutaneous transplantation experiments
(Sacchetti et al, 2016), cells and 3-month-old NSG male mice were
pre-treated with tamoxifen as described above. The following day,
106 cells were suspended in 1 ml of cold undiluted reduced growth
factor Matrigel (BD cat n 356230; kept on ice) and immediately
injected subcutaneously in anesthetised NSG mice with a ice-cold
1 ml syringe (the needle was kept subcutaneously for 1 min to allow
solidification of the Matrigel). Mice were humanely killed 2 weeks
after injection and Matrigel plugs were explanted and analysed.
Ethics
Healthy donor mesoangioblasts were obtained from muscle biopsies
according to the protocol “Evaluation of regenerative properties of
human mesoangioblasts”, submitted to the San Raffaele Scientific
Institute Ethical Committee by G. Cossu and authorised on 20th
February 2007. All patients signed informed consent. DMD human
mesoangioblasts were isolated from muscle biopsies kindly
provided by Dr. Yvan Torrente (University of Milan, Italy). Human
cell work in the Tedesco laboratory was conducted under approval
of the NHS Health Research Authority Research Ethics Committee
reference no. 13/LO/1826; IRAS project ID no. 141100.
Statistics
Values were expressed as the mean  SEM. Significance of the dif-
ferences between means was assessed by Student’s t-test or by one-
way analysis of variance (ANOVA) followed by Tukey’s post hoc
analyses test when multiple comparisons were required. A probabil-
ity of less than 5% (P < 0.05) was considered to be statistically
significant. Data were analysed with GraphPad Prism 6.
Expanded View for this article is available online.
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The paper explained
Problem
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disor-
der caused by mutations in the dystrophin gene. The large size of the
dystrophin gene makes very difficult to clone its full cDNA into
conventional delivery vectors for DMD gene therapy.
Results
hTERT- and Bmi1-mediated reversible immortalisation of human
muscle progenitors allowed their genetic correction with a novel
human artificial chromosome (HAC) containing the entire dystrophin
locus (DYS-HAC2). Finally, generation of a next-generation multifunc-
tional HAC containing both dystrophin locus and the immortalising
genes established a new platform for complex gene transfer.
Impact
This study provides the first evidence of translation of HAC technology
to clinically relevant human muscle progenitors for ex vivo gene ther-
apy of DMD and describes the development of the largest gene ther-
apy vector to date.
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